Author name: Ananta Kar

Ananta is wrapping up her postgraduate studies in Comparative Literature whilst juggling a solid two-year writing career. She cut her teeth as a sports journalist before discovering her true passion: India's exploding gaming scene. These days, she's obsessed with how gaming culture is reshaping the country, and her academic research chops bring unexpected depth to every piece. Whether dissecting esports trends or exploring biologics in India, renewable energy, electric Vehicles & Smart Transportation topics, Ananta writes with the curiosity of a researcher and the energy of someone who genuinely loves what they do.

Avatar photo

India’s $572 Billion Opportunity: Pharma’s Gateway to Europe Opens Wide

A generic drug manufacturer in Gujarat can now access all 27 European Union markets without paying a single rupee in tariffs. A medical device producer in Maharashtra suddenly faces European competition arriving 15 per cent cheaper than before. Both outcomes stem from the same transformative agreement. The India-EU Free Trade Agreement, sealed on 27th January […]

India’s $572 Billion Opportunity: Pharma’s Gateway to Europe Opens Wide Read More »

BYD’s Indian Gambit: How China’s Ev Giant Plans to Bypass 70% Tariffs

The world’s largest electric vehicle manufacturer faces a peculiar problem in India: too much demand and no legal way to satisfy it. BYD, the Shenzhen colossus that eclipsed Tesla‘s 2025 volumes with over five million annual electric vehicle sales globally, has exhausted its dealer order books in India—hundreds of orders pending, fourth quarter 2025 inventory

BYD’s Indian Gambit: How China’s Ev Giant Plans to Bypass 70% Tariffs Read More »

Cheaper Cancer Drugs, Threatened Patents: India-EU Trade’s Double Edge for Pharma

A cancer patient in Mumbai could soon pay 15 per cent less for European biologics. An Indian pharmaceutical manufacturer might capture new European markets worth billions. Yet the same trade agreement enabling both outcomes has sparked fierce debate about whether India‘s generic drug industry—supplying 20 per cent of global generics and keeping essential medicines affordable

Cheaper Cancer Drugs, Threatened Patents: India-EU Trade’s Double Edge for Pharma Read More »

India’s $1 Trillion Ev Dream: What Budget 2026 Must Deliver

India’s electric vehicle revolution has reached an inflection point. With 2.3 million electric vehicle registrations cresting 8 per cent of 2025 sales, the sector stands poised between genuine transformation and stalled momentum. As Finance Minister Nirmala Sitharaman prepares the Union Budget 2026-27 for its 1st February unveiling, the electric vehicle ecosystem besieges Delhi not with

India’s $1 Trillion Ev Dream: What Budget 2026 Must Deliver Read More »

The Mother of All Deals: India and EU Forge History’s Largest Free Trade Zone

Twenty-seven years. That’s how long it took for Europe and India to finally shake hands on what Ursula von der Leyen calls “the mother of all deals.” At New Delhi‘s 16th India-EU Summit on 27th January 2026, after launching in 2007, stalling in 2013, and reviving in June 2022, the India-EU Free Trade Agreement crystallised

The Mother of All Deals: India and EU Forge History’s Largest Free Trade Zone Read More »

The €200 Billion Game-Changer: How EU-India Trade Will Transform Medicine and Motors

After marathon negotiations resuming in June 2022, the European Union and India finally crystallised their Free Trade Agreement in early 2026, unleashing a bilateral behemoth poised to double trade volumes to €200 billion by 2030. This isn’t merely another trade pact shuffling tariff schedules—it’s a strategic recalibration that promises to make cancer treatments cheaper for

The €200 Billion Game-Changer: How EU-India Trade Will Transform Medicine and Motors Read More »

How Biologics Slashed Asthma Hospitalisations by 85% in Disadvantaged Children

A Black child living in a high-deprivation neighbourhood with severe asthma faces a brutal arithmetic: twice the hospitalisation rate, three times the emergency department visits, and a relentless cascade of oral steroids that stunts growth and weakens bones whilst barely controlling symptoms. For families navigating poverty, inadequate housing, and limited healthcare access, paediatric asthma isn’t

How Biologics Slashed Asthma Hospitalisations by 85% in Disadvantaged Children Read More »

The 5.5mL Breakthrough: How Two Giants Solved Biologics’ Injection Problem

Imagine requiring a life-saving cancer immunotherapy, autoimmune treatment, or obesity medication that demands injecting 5 millilitres of thick, viscous liquid through a needle at home—liquid so concentrated it flows like honey, taking minutes of sustained pressure to deliver whilst you hold perfectly still. This isn’t a hypothetical nightmare; it’s the rapidly approaching reality for millions

The 5.5mL Breakthrough: How Two Giants Solved Biologics’ Injection Problem Read More »

The Psoriasis Price Revolution: How India Found Its Most Cost-Effective Biologic

Twenty million Indians live with psoriasis, and for 80 per cent suffering moderate-to-severe plaque variants, the disease doesn’t merely affect skin—it devastates quality of life, relationships, and economic participation. Biologics have transformed what’s medically possible, delivering clearance rates unimaginable with conventional therapies, yet in India’s healthcare landscape, efficacy alone never determines what reaches patients. Cost

The Psoriasis Price Revolution: How India Found Its Most Cost-Effective Biologic Read More »

The 18-Month Stranglehold: Why Regulatory Delays Are Killing Biologics Innovation

The biologics revolution—promising cures for cancer, genetic disorders, and autoimmune diseases—faces an unexpected executioner: not inadequate science, not manufacturing capacity, but regulatory bureaucracy. Whilst laboratories perfect cell cultures and purification cascades, drugs languish in approval pipelines for 12 to 18 months, inflating development costs by 30 to 50 per cent and postponing life-saving treatments by

The 18-Month Stranglehold: Why Regulatory Delays Are Killing Biologics Innovation Read More »

Scroll to Top